Abstract
Symptomatic drug-induced hepatic adverse events due to trovafloxacin, a new fluoroquinolone antibiotic, are uncommon, but recent severe reactions have led to restriction on its use. We report the clinical course and computed tomography findings in a patient who developed acute liver failure shortly after commencing treatment with trovafloxacin. Extensive hepatic necrosis occurred and the patient ultimately died of her liver disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
